The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19

Zelyn Lee, Craig R Rayner, Jamie I Forrest, Jean B Nachega, Esha Senchaudhuri, Edward J Mills, Zelyn Lee, Craig R Rayner, Jamie I Forrest, Jean B Nachega, Esha Senchaudhuri, Edward J Mills

Abstract

The efficacy and safety of hydroxychloroquine (HCQ) for the prevention and treatment of COVID-19 has received great attention, and most notably, the enthusiasm for HCQ has been one of politicization rather than science. Laboratory studies and case series published early in the pandemic supported its efficacy. The scientific community raced to conduct observational and randomized evaluations of the drug in all stages of the disease, including prophylaxis, early treatment, and advanced disease. Yet a divisive media response affected recruitment, funding, and subsequent enthusiasm for continuing scientific investigations. Of the more than 300 HCQ trials registered, fewer than 50% report having recruited any patients, and most trials might fail to achieve any useful portions of their intended sample size. Multiple observational studies and two large randomized trials have demonstrated HCQ does not offer efficacy against COVID-19 in hospitalized patients. Prophylaxis studies and early treatment studies provided heterogeneous results and are plagued by low event rates and poor study outcome monitoring. Emerging high-quality evaluations of prophylaxis and early treatment do not support a role for HCQ in these populations. The story of HCQ for COVID-19 has followed a pattern of initial enthusiasm supported by poor quality evidence, followed by disappointment based on more rigorous evaluations. The experience of HCQ in the COVID-19 era calls for the depoliticization of science away from media glare.

Figures

Figure 1.
Figure 1.
Number of active registered trials investigating hydroxychloroquine by date among patient populations of prophylaxis, outpatient, and hospitalized settings. This figure appears in color at www.ajtmh.org.

References

    1. Beigel JH, et al. 2020. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med (Epub ahead of print). 10.1056/NEJMoa2007764.
    1. Horby P, et al. 2020. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med (Epub ahead of print). doi: 0.1056/NEJMoa2021436.
    1. Sinha N, Balayla G, 2020. Hydroxychloroquine and COVID-19. Postgrad Med J 96: 550–555.
    1. Yao X, et al. 2020. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 71: 732–739.
    1. Gautret P, et al. 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56: 105949.
    1. Intson K, Kumar S, Botta A, Neckles R, Leung C, Jawaid A, 2020. An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19. Swiss Med Wkly 150: w20262.
    1. Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, de Castro N, 2020. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 50: 384.
    1. Piszczatoski CR, Powell J, 2020. Emergency authorization of chloroquine and hydroxychloroquine for treatment of COVID-19. Ann Pharmacother 54: 827–831.
    1. Geleris J, et al. 2020. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 382: 2411–2418.
    1. Million M, et al. 2020. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 35: 101738.
    1. Rosenberg ES, et al. 2020. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA 323: 2493–2502.
    1. Rodrigo C, Fernando SD, Rajapakse S, 2020. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. Clin Microbiol Infect 26: 979–987.
    1. Ramireddy A, et al. 2020. Experience with hydroxychloroquine and azithromycin in the coronavirus disease 2019 pandemic: implications for QT interval monitoring. J Am Heart Assoc 9: e017144.
    1. Nina PB, Dash AP, 2020. Hydroxychloroquine as prophylaxis or treatment for COVID-19: what does the evidence say? Indian J Public Health 64 (Supplement): S125–S127.
    1. Das S, Bhowmick S, Tiwari S, Sen S, 2020. An updated systematic review of the therapeutic role of hydroxychloroquine in coronavirus disease-19 (COVID-19). Clin Drug Investig 40: 591–601.
    1. Mehra MR, Desai SS, Ruschitzka F, Patel AN, 2020. RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet (Epub ahead of print, 22 May 2020). 10.1016/S0140-6736(20)31180-6.
    1. Meyerowitz EA, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand JA, Callahan MV, Kim AY, Reeves PM, Poznansky MC, 2020. Rethinking the role of hydroxychloroquine in the treatment of COVID-19. Faseb J 34: 6027–6037.
    1. Park JJH, Decloedt EH, Rayner CR, Cotton M, Mills EJ, 2020. Clinical trials of disease stages in COVID 19: complicated and often misinterpreted. Lancet Global Health 8: e1249–e1250.
    1. Randomise Evaluation of COVID-19 Therapy , 2020. Statement from the Chief Investigators of the Randomised Evaluation of COVID-19 thERapY (RECOVERY) Trial on Hydroxychloroquine, June 5, 2020. Available at: .
    1. MORU Tropical Health Network , 2020. COPCOV Trial. Available at: . Accessed October 28, 2020.
    1. , 2020. Crown Coronation: COVID-19 Research Outcomes Worldwide Network for Coronavirus Prevention (CROWN CORONA). Available at: .
    1. Pan H, 2020. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv. doi: 2020.2010.2015.20209817.
    1. US Food and Drug Administration , 2020. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. Available at: .
    1. Infante M, Ricordi C, Alejandro R, Caprio M, Fabbri A, 2020. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. Expert Rev Anti Infect Ther 1–12.
    1. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M, 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6: 16.
    1. Cohen MS, 2020. Hydroxychloroquine for the prevention of COVID-19 - searching for evidence. N Engl J Med 383: 585–586.
    1. Garcia-Albeniz X, Del Amo J, Polo R, Morales Asencio JM, Hernan MA, 2020. Brief communication: a meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. medRxiv. doi: 2020.2009.2029.20203869.
    1. Rajasingham R, et al. 2020. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. medRxiv. doi: 2020.2009.2018.20197327.
    1. Cytel Inc , 2020. COVID-19 Response: New Opportunities and Implications for the Future of Drug Development in Emerging Economies. Available at: .
    1. , 2020. Treatment for COVID-19 in High-Risk Adult Outpatients (NCT04354428). Available at: .
    1. Abena PM, et al. 2020. Chloroquine and hydroxychloroquine for the prevention or treatment of COVID-19 in africa: caution for inappropriate off-label use in healthcare settings. Am J Trop Med Hyg 102: 1184–1188.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa